Efficacy of Qili Qiangxin Capsules combined with western medicine in treating chronic heart failure and its impact on cardiac function, inflammatory factors and fibrosis indexes
Abstract：Objective To investigate the efficacy of Qili Qiangxin Capsules combined with western medicine in the treatment of chronic heart failure (CHF), and to observe its impact on cardiac function, inflammatory factors and fibrosis index levels. Methods Ninety CHF patients were selected; by using the random number table method, they were divided into control group and observation group, with 45 cases in each group. The control group conventionally adopted western medicine therapy, while the observation group was additionally administered Qili Qiangxin Capsules. The efficacy was compared after 8 weeks of treatment between the two groups. ResultsAfter 8 weeks of treatment, the symptom scores of patients in the two groups all significantly decreased, while the scores for asthma, limb edema and chills with cold extremities in the observation group were all significantly lower than those in the control group (all P<0.05). The cardiac function of both groups significantly improved after 8 weeks of treatment as compared to before (P<0.05); LVEF and stroke volume (SV) in the observation group were significantly higher than those in the control group, while left ventricular enddiastolic diameter (LVEDD) and left ventricular endsystolic diameter (LVESD) were significantly lower than those in the control group (both P<0.01). After treatment, the levels of serum tumor necrosis factorα (TNF-α), NT-proBNP and hypersensitive Creactive protein (hs-CRP) in the observation group were significantly lower than those in the control group (all P<0.01); the levels of serum transforming growth factorβ1 (TGF-β1), fibroblasts growth factor23 (FGF-23) and tissue inhibitor of matrix metallo protease1 (TIMP1) in the observation group were significantly reduced compared with those in the control group (all P<0.05). The total effective rate in the observation group after treatment was significantly higher than that in the control group (93.33% vs. 68.89%), and the difference was statistically significant (P<0.05). ConclusionCompared with conventional western medicine therapy, the clinical application of Qili Qiangxin Capsules combined with western medicine in the treatment of CHF could further reduce inflammatory damage and improve cardiac function, which effectively relieves CHF.
刘莹，刘耀武，罗国帅. 芪苈强心胶囊联合西药治疗慢性心力衰竭疗效及其对心功能、炎性因子、纤维化指标的影响[J]. 实用心电学杂志, 2024, 33(05): 479-484.
LIU Ying, LIU Yaowu, LUO Guoshuai. Efficacy of Qili Qiangxin Capsules combined with western medicine in treating chronic heart failure and its impact on cardiac function, inflammatory factors and fibrosis indexes. JOURNAL OF PRACTICAL ELECTROCARDIOLOGY, 2024, 33(05): 479-484.
